
Reflex
OperatingBrightlamp, Inc.
Healthcare · Indianapolis, IN · Founded 2018
Five-second neurological vital
Financials
FY2020–FY2022 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Fundraising history
Team
2 people
Kurtis Sluss is an engineer, inventor, and TechCrunch Disrupt Alumnus. His background is in chemical engineering and organic chemistry from Purdue University with a focus on novel drug design and disease detection methods. An interest in advanced programming and its application in medicine led him to create a novel method to detect and classify cancerous proteins through machine learning. Now, Kurtis is translating this knowledge to neuro-biomechanical evaluations using a mobile phone. He leads Brightlamp as co-Founder and CEO to maintain the vision of creating affordable diagnostic technologies on a global scale.

Michael Heims serves as the Chief Financial Officer at brightlamp. Previously to brightlamp, Michael worked at Eli Lilly and Company as a Financial Analyst managing a budget of more than $200M. Michael left Lilly to join a role with a medium-sized private equity firm, where he grew a portfolio company from $2M in EBITDA to over $30M in less than 2 years by working as the sole acquisition advisor. While there, he contributed to a variety of aspects of due diligence of prospective companies, from quality of earnings to forecasting models, and everything in between.
Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 1 of 4 annual reports (FY2022–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.